Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer (Q36617642)

15 August 2017

Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

Earle CC

1

1 reference

15 August 2017

Evans WK

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

80

1 reference

15 August 2017

5-6

1 reference

15 August 2017

815-820

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690426

15 August 2017

0 references

cites work

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

Recent advances in the treatment of non-small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

The cost of managing lung cancer in Canada.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

Diagnostic and therapeutic approaches to lung cancer in Canada and their costs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

A clinician's guide to cost-effectiveness analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

28 June 2018

Cancer statistics, 1996.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

Does knowledge guide practice? Another look at the management of non-small-cell lung cancer

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362269

Cost of combined modality interventions for stage III non-small-cell lung cancer

20 September 2018

1 reference

12 December 2020

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

1 reference

12 December 2020

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

12 December 2020

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer

1 reference

12 December 2020

The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer

1 reference

12 December 2020

Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer

1 reference

12 December 2020

A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer

1 reference

12 December 2020

New drugs in the treatment of non-small cell lung cancer.

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690426

7 January 2021

inferred from DOI database lookup

Chemotherapy in non-small cell lung cancer

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690426

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6690426

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

10360660

1 reference